Giuseppina Biondi
Overview
Explore the profile of Giuseppina Biondi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colella A, Biondi G, Marrano N, Francioso E, Fracassi L, Crovace A, et al.
Vet Sci
. 2024 Aug;
11(8).
PMID: 39195834
Cell-based therapy using insulin-producing cells (IPCs) is anticipated as an alternative treatment option to insulin injection or pancreatic islet transplantation for the treatment of diabetes mellitus in both human and...
2.
Biondi G, Marrano N, Borrelli A, Rella M, DOria R, Genchi V, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203279
Diabetes mellitus is a chronic metabolic disease, the prevalence of which is constantly increasing worldwide. It is often burdened by disabling comorbidities that reduce the quality and expectancy of life...
3.
Marrano N, Biondi G, Borrelli A, Rella M, Zambetta T, Di Gioia L, et al.
Biomolecules
. 2023 Jan;
13(1).
PMID: 36671568
Type 2 diabetes (T2D) and Alzheimer's diseases (AD) represent major health issues that have reached alarming levels in the last decades. Although growing evidence demonstrates that AD is a significant...
4.
Caruso I, Marrano N, Biondi G, Genchi V, DOria R, Sorice G, et al.
Diabetes Metab Res Rev
. 2023 Jan;
39(3):e3609.
PMID: 36637256
Hyperglucagonemia is one of the 'ominous' eight factors underlying the pathogenesis of type 2 diabetes (T2D). Glucagon is a peptide hormone involved in maintaining glucose homoeostasis by increasing hepatic glucose...
5.
DOria R, Genchi V, Caccioppoli C, Calderoni I, Marrano N, Biondi G, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430774
Obesity with its associated complications represents a social, economic and health problem of utmost importance worldwide. Specifically, obese patients carry a significantly higher risk of developing cardiovascular disease compared to...
6.
Palma G, Sorice G, Genchi V, Giordano F, Caccioppoli C, DOria R, et al.
Int J Mol Sci
. 2022 Jul;
23(13).
PMID: 35806353
Obesity is a chronic disease caused by an excess of adipose tissue that may impair health by altering the functionality of various organs, including the lungs. Excessive deposition of fat...
7.
Biondi G, Marrano N, Borrelli A, Rella M, Palma G, Calderoni I, et al.
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628332
The dysregulation of the β-cell functional mass, which is a reduction in the number of β-cells and their ability to secure adequate insulin secretion, represents a key mechanistic factor leading...
8.
Biondi G, Marrano N, Dipaola L, Borrelli A, Rella M, DOria R, et al.
Diabetes
. 2022 May;
71(8):1763-1771.
PMID: 35612429
We evaluated the role of the p66Shc redox adaptor protein in pancreatic β-cell insulin resistance that develops under lipotoxic conditions and with excess body fat. Prolonged exposure to palmitate in...
9.
Tumminia A, Romano R, Brugaletta G, Scicali R, Biondi G, Oliveri R, et al.
Nutr Metab Cardiovasc Dis
. 2022 May;
32(7):1635-1641.
PMID: 35508458
Background And Aims: Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase was early identified as a promising therapeutic candidate against COVID-19. Our aim was to evaluate the impact...
10.
Cignarelli A, Genchi V, Le Grazie G, Caruso I, Marrano N, Biondi G, et al.
Front Endocrinol (Lausanne)
. 2022 Mar;
13:846903.
PMID: 35265043
Accumulating evidence supports the early use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose transporter-2 inhibitors (SGLT-2is) for the treatment of type 2 diabetes. Indeed, these compounds exert numerous...